Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) ...

Denmark on Thursday sharply raised its economic growth forecast for 2025, due in part to the pharmaceuticals industry, which ...

Denmark is heading for its worst year of job losses since the Covid pandemic, as sweeping cuts at pharmaceutical giant Novo ...

Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the Danish Patient ...

Denmark raised its growth projections for this year and the next, suggesting Novo Nordisk A/S is able to fuel the Nordic ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

Novo Nordisk's weight on GDP, jobs, and exports is reshaping Denmark's growth story despite layoffs and tariff headwinds.

Weaker prospects for pharmaceutical giant Novo Nordisk A/S (NYSE:NVS) have prompted Denmark's economic ministry to cut its 2025 GDP forecast, now expecting just 1.4% growth, down 1.5 percentage points ...

The government has just negotiated a significant price reduction for the diabetes and weight-loss treatment. The stock jumped ...

LONDON () -Novo Nordisk shares rose 5% on Wednesday after analysts said that U. price cuts for the Danish drugmaker's ...

Denmark’s Novo Nordisk saw its shares rise 4% to 298.50 kroner today, after it announced positive headline results from a Phase II clinical trial with amycretin in people with type 2 diabetes.

FRANKFURT, Germany — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the ...